TP53 and acute promyelocytic leukemia: The mechanism of action suggested in APL and other studies is that miR-218 can inhibit BMI-1, which leads to an increase of p16INK4A to halt the cell cycle and p19ARF to inhibit p53 degradation [24,25,26].